S9. GLUCOCORTICOIDS

All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1. ALCOHOL

Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L.

- Air Sports (FAI)
- Archery (WA)
- Automobile (FIA)
- Motorcycling (FIM)
- Powerboating (UIM)

P2. BETA-BLOCKERS

Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated.

- Archery (WA)*
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Shooting (ISSF, IPC)*
- Skiling/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
- Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea.

*Also prohibited Out-of-Competition

Including, but not limited to:
Acebutolol; alprenolol; atenolol; betaxolol; bisoprolol; bunolol; carteolol; carvedilol; celiprolol; esmolol; labetalol; levobunolol; metipranolol; metoprolol; nadolol; oxprenolol; pindolol; propranolol; sotalol and timolol.

For More Information Contact:
Director General
National Anti Doping Agency
A-Block, Pragati Vihar Hostel,
Lodhi Road, New Delhi - 110 003
Telefax : 011-24368248 24368274
E-mail : info.nada@nic.in
Website : www.nada.nic.in

National Anti Doping Agency
India

PROHIBITED LIST - 2015

This List is effective from 1 January 2015

www.nada.nic.in

Play fair
THE 2015 PROHIBITED LIST
WORLD ANTI-DOPING CODE
Valid from 1 January 2015

In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as "Specified Substances" except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3.

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES
(IN- AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES

S0. NON-APPROVED SUBSTANCES

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g., drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1. ANABOLIC AGENTS

Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)
   a. Exogenous* AAS, including:
      1-androstenediol (5α-androst-1-ene-3β,17β-diol)
      1-androstenedione (5α-androst-1-ene-3β,17-dione)
      bolandiol (estr-4-ene-3β,17β-diol)
      bolasterone
      boldione (androsta-1,4-diene-3β,17-dione)
      calusterone
clostebol; danazol [(1,2) oxazolo[4,5,2,3]pregna-4-ene-20-yne-17β-ol]
      dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-diene-3-one)
      desoxymethyltestosterone (17α-methyl-5α-androst-2-ene-17β-ol)
      drostanolone
      ethylestrenol (19-norpregna-4-ene-17β-ol)
      fluoxymesterone
      formebolone
      furazabiol (17α-methyl[1,2,5]oxadiazolo[3′,4′:2,3]-5α-androstan-17β-ol)
      gestrinone
      4-hydroxytestosterone (4,17β-dihydroxyandrost-4-ene-3-one)
      mestanalone
      mesterolone
      metenolone
      methandienone (17β-hydroxy-17α-methylandrosta-1,4-diene-3-one)
methandriol
methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androst-3-one)
methylidienolone (17β-hydroxy-17α-methylenes-4,9-dien-3-one)
methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)
methyltestosterone (17β-hydroxy-17α-methyl ether-4-en-3-one)
methylenevidiolone
metribolone (methyltrieneolone, 17β-hydroxy-17α-methylenes-4,9,11-trien-3-one)
mibolerone
androlone
19-norandrostenedione (estr-4-ene-3β,17-dione)
norboleton; norclostebol
norethandrolone; oxaboline; oxandrolone; oxymesterone; oxymetholone
prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1’H-pyrazolo[3,4:2,3]-5α-androstane)
quinbolone
stanozolol
stenbolone
1-testosterone (17β-hydroxy-5α-androst-1-en-3-one);
tetrahydrogestrinone (17-β-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one);
trenbolone (17β-hydroxyest-4,9,11-trien-3-one);
and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous** AAS when administered exogenously:
   androstenediol (androst-5-en-3β,17β-diol);
   androstenedione (androst-4-en-3β,17β-diol);
dihydrotestosterone (17β-hydroxy-5α-androstan-3-one);
prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one);
testosterone;
and their metabolites and isomers, including but not limited to:
5α-androstane-3α,17α-diol
5α-androstane-3α,17β-diol
5α-androstane-3β,17β-diol
5α-androstane-3β,17α-diol
5β-androstane-3β,17β-diol
androstan-4-ene-3α,17α-diol
androstan-4-ene-3α,17β-diol
androstan-4-ene-3β,17α-diol
androstan-5-ene-3α,17α-diol
androstan-5-ene-3α,17β-diol

For purposes of this section:
* "exogenous" refers to a substance which is not ordinarily produced by the body naturally.
** "endogenous" refers to a substance which is ordinarily produced by the body naturally.
androst-5-ene-38,17α-diol
4-androstenediol (androst-4-ene-38,17β-diol)
5-androstenedione (androst-5-ene-3,17-dione)
androstenedione (3β-hydroxy-5α-androstan-17-one);
epi-dihydrotestosterone; epitostosterone; etiocholanone
7α-hydroxy-DHEA
7β-hydroxy-DHEA
7-keto-DHEA; 19-norandrostenedione; 19-noretiocholanolone.

2. Other Anabolic Agents
including but not limited to:
Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine and ostarine), tibolone, zeralon and zilpaterol.

52. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS
The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:
1. Erythropoietin-Receptor agonists:
   1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. darbepoetin (DEPO); erythropoietin (EPO); EPO-FC; EPO-mimetic peptides (EMP), e.g. CT 530 and peginesatide; and methoxy polyethylene glycol-epoetin beta (CERA);
   1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290, asialo EPO and carbamylation EPO;
2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. argon, xenon;
3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and triptorelin, in males;
4. Corticotrophins and their releasing factors, e.g. corticorelin;
5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; and GH-Releasing Peptides (GHRPs), e.g. alesmamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2).
Additional prohibited growth factors:
- Fibroblast Growth Factors (FGFs);
- Hepatocyte Growth Factor (HGF);
- Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs);
- Platelet-Derived Growth Factor (PDGF);
- Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

53. BETA-2 AGONISTS
All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

54. HORMONE AND METABOLIC MODULATORS
The following hormones and metabolic modulators are prohibited:
1. Aromatase inhibitors including, but not limited to: aminoglutethimide; anastrozole; androst-1,4,6-triene-3,17-dione (androstatrienedione); 4-androstene-3,6,17 trione (6-oxo); exemistane; formestane; letrozole and testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene; tamoxifen and toremifene.
3. Other anti-estrogenic substances including, but not limited to: clomiphene; cyclofenil and fulvestrant.
4. Agents modifying myostatin function(s) including, but not limited to: myostatin inhibitors.
5. Metabolic modulators:
   5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor β (PPARβ) agonists, e.g. GW 1516;
   5.2 Insulins;
   5.3 Trime disproportionate.

55. DIURETICS AND OTHER MASKING AGENTS
The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).
Including, but not limited to:
- Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannnitol.
- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrylic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.
Except:
- Drospirenone; pamabrom; and topical dorzolamide and brinzolamide.
- Local administration of felypressin in dental anaesthesia.
The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, caphine, ephedrine, methylephedrine and pseudoephedrine in conjuction with a
diuretic or masking agent, will be considered as an *Adverse Analytical Finding* unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent.

**PROHIBITED METHODS**

**M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS**

The following are prohibited:

1. The *Administration* or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

2. Artificially enhancing the uptake, transport or delivery of oxygen.

Including, but not limited to:

*Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products*, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen.

3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

**M2. CHEMICAL AND PHYSICAL MANIPULATION**

The following are prohibited:

1. *Tampering*, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.

Including, but not limited to:

- Urine substitution and/or adulteration, e.g. proteases.

2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.

**M3. GENE DOPING**

The following, with the potential to enhance sport performance, are prohibited:

1. The transfer of polymers of nucleic acids or nucleic acid analogues;

2. The use of normal or genetically modified cells.

**SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION**

In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition:

**PROHIBITED SUBSTANCES**

**S6. STIMULANTS**

All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

Stimulants include:

a. Non-Specified Stimulants:

Adrafinil; amfepramone; amfetamine; amfetaminil; amphetamine; benfluorex; benzylpiperazine; bromantan; clobenzorex; cocaine; croproamide; crotetamide; fencamine; fenfluramine; fenproporex; fortinaracetam [4-phenylpiracetam (carphedon)]; furfrenorex; mefenorex; mephentermine; mesocarb; metamfetamine (d-); p-methylamphetamine; modafinil; norgrenfluramine; phonidemazine; phentermine; prenylamine and prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

b: Specified Stimulants.

Including, but not limited to:

Benzetamine; cathine**; cathinone and its analogues, e.g. methedrone, methedrone, and a - pyrroliodinovlerophenone; dimethylamphetamine; etphonervine***; epinephrine**** (adrenaline); etamivan; etiamfetamine; etilefjaine; fampofazone; fenbutrazate; fencamamin; heptaminol; hydroxyametamine (parahydroxyamphetamine); isometheptene; levmetametamine; melofenoxate; methylenedioxymethamphetamine; methylephedrine***; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine (methylsymphefrine); pemoline; pentetrazol; phenylpalmitate and its derivatives; phenmetrazine; propylhexedrine; pseudoephedrine*****; selegiline; sibutramine; strychnine; tetrametamine (methylenedioxymethamphetamine), thunoamine and other substances with a similar chemical structure or similar biological effect(s).

Except:

Imidazole derivatives for topical/ophtalmic use and those stimulants included in the 2015 Monitoring Program*.

**S7. NARCOTICS**

Prohibited:

Buprenorphine; dextromoramide; diamorphine (heroin); fentanyl and its derivatives; hydromorphone; methadone; morphine; oxycodone; oxymorphone; pentazocine and pethidine.

**S8. CANNABINOIDS**

Prohibited:

+ Natural, e.g. cannabis, hashish and marijuana, or synthetic
+ Δ9-tetrahydrocannabinol (THC).

* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2015 Monitoring Program, and are not considered Prohibited Substances.

** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre.

*** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre.

**** Ephedrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophtalmologic, or co-administration with local anaesthetic agents.

***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre.